OncoMatch/Clinical Trials/NCT06183489
Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma
Is NCT06183489 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Elranatamab for smoldering multiple myeloma.
Treatment: Elranatamab — This is a multicenter, single arm, open-label, Phase 2 study in high risk smoldering myeloma patients. The primary objective is to determine the efficacy of Elranatamab in patients with previously untreated high-risk SMM. The key-secondary objective is to determine the safety of Elranatamab in patients with previously untreated high-risk SMM.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic therapy for multiple myeloma
Previous therapy with any systemic therapy for multiple myeloma
Cannot have received: plasmapheresis
Exception: within 14 days of eligibility confirmation
Subject has had plasmapheresis within 14 days of elegibility confirmation
Lab requirements
Blood counts
Absolute neutrophil count ≥1.0 x 10^9/L (≥1000/μL); Platelet count ≥75 x 10^9/L
Kidney function
Liver function
AST ≤2.5 x ULN; ALT ≤2.5 x ULN; total bilirubin ≤1.5 x ULN (except congenital bilirubinemia, then direct bilirubin ≤2.0 x ULN)
Absolute neutrophil count ≥1.0 x 10^9/L (ie, ≥1000/μL); Platelet count ≥75 x 10^9/L; AST ≤2.5 x ULN; ALT ≤2.5 x ULN; Total bilirubin ≤1.5 x ULN, except in subjects with congenital bilirubinemia, such as Gilbert syndrome (in which case direct bilirubin ≤2.0 x ULN is required)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06183489 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages